KK
CRSP icon

KLP Kapitalforvaltning’s CRISPR Therapeutics CRSP Stock Holding History

KLP Kapitalforvaltning’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$899K Buy
18,900
+1,700
+10% +$89.7K ﹤0.01% 1095
2025
Q4 		$902K Hold
17,200
– – ﹤0.01% 1093
2025
Q3 		$1.11M Hold
17,200
– – ﹤0.01% 967
2025
Q2 		$837K Buy
17,200
+1,100
+7% +$42.6K ﹤0.01% 1078
2025
Q1 		$548K Hold
16,100
– – ﹤0.01% 1250
2024
Q4 		$634K Buy
+16,100
New +$760K ﹤0.01% 1229

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KLP Kapitalforvaltning's CRSP Position: Q1 2026 in Review

KLP Kapitalforvaltning increased its CRISPR Therapeutics (CRSP) stake by 9.9% in Q1 2026, buying an estimated $89.7K and bringing the position to 18,900 shares worth $899K. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

KLP Kapitalforvaltning first reported a position in CRSP in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.11M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • KLP Kapitalforvaltning held 18,900 shares of CRISPR Therapeutics worth $899K as of Q1 2026.
  • KLP Kapitalforvaltning bought 1,700 CRISPR Therapeutics shares in Q1 2026, an estimated $89.7K.
  • CRISPR Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q1 2026, its #1095 holding.
  • KLP Kapitalforvaltning first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • KLP Kapitalforvaltning's CRISPR Therapeutics position peaked at $1.11M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2026, filed 29 Apr 2026.